FLT3 and leukemia: On this basis, an anti-FLT3 MAb (LY3012218) was developed and evaluated in a phase I trial in R/R AML (NCT008879269), but failed to demonstrate clinical efficacy; the failure was attributed to the high leukemia burden and to the non-optimized FcR, which was unable to activate ADCC [91].